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Post-operative atrial fibrillation (POAF) affects 10% to 60%
of patients following cardiac surgery, creating increased
thrombo-embolism risk and hemodynamic compromise and
resulting in prolonged length of stay and increased mortality
(1). The impact of POAF extends beyond that of the
immediate hospitalization with up to 25% developing on-
going late AF (1). POAF has a substantial impact on
healthcare resources with estimates of over $2 billion/year in
treatment-related costs in the United States alone, a figure
likely to increase given the surgical population is aging with an
increasing number of comorbidities that predispose to AF (1).
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Thus, it is timely that Swartz et al. (2), in this issue of the
Journal, report their findings from a prospective study that
implicates pre-existing selective left atrial (LA) fibrosis in the
pathogenesis of POAF and that recognizes the potential for
serum markers of collagen synthesis (C-terminal peptide from
pro-collagen-I [PICP] and N-terminal peptide from pro-
collagen III [PIIINP]) to identify fibrosis risk. Importantly,
there was a modest linear correlation between serum PICP and
percentage of LA fibrosis. This study adds to prior work from
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and development of post-surgical AF, and it potentially has
wider implications for patients at risk of AF outside of this
surgical context (3). Critically, the study identified a simple
peripheral marker of atrial fibrosis and hence of AF risk.
Fibrosis is a fundamental component of atrial structural
remodeling that contributes to AF persistence and may be
viewed as a final common endpoint of a range of different
cardiac insults. Development of regional fibrosis results in
electrical uncoupling of adjacent muscle bundles leading to
discontinuities in transverse conduction, localized regions of
conduction slowing and block, and increased heterogeneity;
the net result being promotion of both focal and macro-re-
entry (4). The spatial distribution and degree of fibrosis have
been shown to influence AF activation frequency and
wave-front dynamics and the development of LA sources
may be predicated on the presence of LA fibrosis (3,5).
Time-dependent increases in fibrosis and atrial substrate
complexity possibly play a critical role in AF progression
from paroxysmal through persistent and permanent forms of
the arrhythmia (6).
The correlates of atrial fibrosis in clinical mapping studies
also include regional low voltage and electrical silence,
conduction slowing with circuitous propagation, and recent
evidence of rotor formation (7–10). It is well recognized
that atrial fibrosis can occur as a result of AF as part of an
arrhythmia-related remodeling process. In addition, condi-
tions associated with atrial stretch and activation of the
renin-angiotensin system including hypertension (11), heart
failure (12), and valvular heart disease (13) all produce a
similar fibrosis-based substrate even before the development
of an atrial arrhythmia. Interestingly, a recent study in
patients with apparently lone AF, showed early evidence of
a similar substrate even though studied at least 2 weeks from
an AF episode (14). Furthermore, emerging data suggests
that in this population the substrate may progress despite
arrhythmia cure (15), raising the possibility that it repre-
sents an underlying primary myopathy (16).
The present study strengthens the notion that despite the
supervening role of transient factors in the development of
POAF, vulnerability to the arrhythmia even in this setting is
critically determined by the presence of existing LA fibrosis.
This may also explain the ongoing long-term risk of AF in
these patients late after cardiac surgery. Beyond the biopsy
evidence of LA fibrosis, the study also demonstrated in-
creased LA levels of collagen I and III in patients who
developed POAF and elevation in LA pro-fibrotic markers
transforming growth factor beta and angiotensin II, provid-
ing a molecular link to the increased fibrosis.
Noninvasive assessment of collagen turnover and fibrosis
has been used to investigate the natural history and treat-
ment of hypertensive heart disease, diastolic dysfunction,
and paroxysmal and persistent AF (17,18). Markers of both
synthesis and degradation are increased in different AF
populations, although results have not always been consistent
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ciated with AF recurrence after catheter ablation and the
likelihood of maintaining sinus rhythm after electrical
cardioversion of persistent AF (19).
In the present study by Swartz et al. (2), elevated markers
of collagen synthesis (PICP and PIIINP) were associated
with POAF. Importantly, they make the unique observation
of a linear correlation between PICP and LA fibrosis,
raising the possibility that simple assay of this peptide may
be used to identify patients with pre-existing substrate and
at heightened risk of POAF. However, important questions
remain unanswered. Of note is that AF patients in this
study were older, had larger left atria, greater left ventricular
mass, higher prevalence of diastolic dysfunction, and more
mitral valve disease. Would these markers still be valid if
both groups of patients were equal in the prevalence of these
baseline factors? These risk factors have been associated
with increased atrial fibrosis and increased levels of these
markers per se. Ultimately, the validity of these markers will
require evaluation in large multicenter studies before we
have a more complete picture of their incremental value and
positive predictive accuracy for development of post-surgical
AF. A simple serum marker with the ability to identify atrial
substrate might also facilitate evaluation of various cardio-
protective and cardioreparative therapeutic interventions.
Looking more broadly, will these markers be useful for
identification of subclinical atrial substrate in other groups
at risk of AF or in diverse AF populations? Correlation of
serum markers with magnetic resonance imaging–based
detection of atrial fibrosis might assist in providing an
answer to the latter question.
This study provides important new information on the
link between serum markers of collagen synthesis and atrial
fibrosis and the risk of developing AF. In doing so, it opens
new avenues of research into this common and yet incom-
pletely understood arrhythmia.
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